NASDAQ:VRUS - Pharmasset Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Pharmasset (NASDAQ:VRUS)

Pharmasset logoPharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.

Receive VRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:VRUS
CUSIPN/A
WebN/A
Phone+1-609-6134100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Pharmasset (NASDAQ:VRUS) Frequently Asked Questions

What is Pharmasset's stock symbol?

Pharmasset trades on the NASDAQ under the ticker symbol "VRUS."

Has Pharmasset been receiving favorable news coverage?

Media stories about VRUS stock have trended positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pharmasset earned a coverage optimism score of 0.41 on Accern's scale. They also assigned media stories about the healthcare company an impact score of 45.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Pharmasset?

Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Pharmasset?

Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100.


MarketBeat Community Rating for Pharmasset (VRUS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pharmasset (NASDAQ:VRUS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/26/2016 forward)

Earnings

Pharmasset (NASDAQ:VRUS) Earnings History and Estimates Chart

Earnings by Quarter for Pharmasset (NASDAQ:VRUS)

Pharmasset (NASDAQ VRUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2011Q4 2011($0.31)($0.33)ViewN/AView Earnings Details
7/25/2011($0.57)($0.60)ViewN/AView Earnings Details
4/25/2011$0.65($0.55)ViewN/AView Earnings Details
2/7/2011Q1 2011($0.28)($0.34)ViewN/AView Earnings Details
11/23/2010Q4 2010($0.23)($0.30)ViewN/AView Earnings Details
8/9/2010Q3 2010($0.26)($0.25)ViewN/AView Earnings Details
5/5/2010Q2 2010($0.23)($0.27)ViewN/AView Earnings Details
2/9/2010Q1 2010($0.22)($0.25)ViewN/AView Earnings Details
11/25/2009Q4 2009($0.27)($0.27)ViewN/AView Earnings Details
8/10/2009Q3 2009($0.20)($0.13)ViewN/AView Earnings Details
5/11/2009Q2 2009($0.25)($0.30)ViewN/AView Earnings Details
2/9/2009Q1 2009($0.26)($0.39)ViewN/AView Earnings Details
8/14/2008Q3 2008($0.31)($0.35)ViewN/AView Earnings Details
5/15/2008Q2 2008($0.22)($0.28)ViewN/AView Earnings Details
2/14/2008Q1 2008($0.28)($0.29)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pharmasset (NASDAQ:VRUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pharmasset (NASDAQ VRUS) Insider Trading and Institutional Ownership History

Insider Trading History for Pharmasset (NASDAQ:VRUS)

Pharmasset (NASDAQ VRUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Pharmasset (NASDAQ VRUS) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Pharmasset (NASDAQ:VRUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pharmasset (NASDAQ:VRUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pharmasset (NASDAQ VRUS) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.